This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.

NCT ID: NCT06666426

Last Updated: 2025-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

171 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their quality of life before and after using the device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 150 women with nighttime urinary incontinence will take part in this prospective, open-label, randomized trial. Participants will use one of two different study devices during the study to manage urine output at night: PureWick™ System or the Hollister® Female Urinary Pouch External Collection Device. Participant device assignment will be random. Participants will use the assigned urine management device overnight while sleeping and will be followed for approximately 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Nocturnal Enuresis Urinary Incontinence (UI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hollister

Group Type ACTIVE_COMPARATOR

Hollister Female Urinary Pouch External Collection Device

Intervention Type DEVICE

The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.

PureWick

Group Type EXPERIMENTAL

PureWick System

Intervention Type DEVICE

The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PureWick System

The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.

Intervention Type DEVICE

Hollister Female Urinary Pouch External Collection Device

The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult Female Participants greater than or equal to 18 years of age at the time of signing the informed consent.
2. Currently use diapers or equivalent at night for urine output management.
3. Willing to comply with all study procedures in this CIP.
4. Provision of signed and dated informed consent form.

Exclusion Criteria

1. Has frequent episodes of bowel incontinence without a fecal management system in place; or
2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or
3. Has urinary tract, vaginal or other chronic infections, active genital herpes; or
4. Has urinary retention; or
5. Is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or
6. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or
7. Has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or
8. Is known to be pregnant at time of enrollment (for women of childbearing age); or
9. Any other condition that, in the opinion of the investigator, would preclude them from participating in the study.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Becton, Dickinson and Company

INDUSTRY

Sponsor Role collaborator

C. R. Bard

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lakeview Clinical Research

Guntersville, Alabama, United States

Site Status

New Horizons Clinical Trials

Chandler, Arizona, United States

Site Status

The Practice of Medicine INC.

Eagle Rock, California, United States

Site Status

Finlay Medical Research

Greenacres City, Florida, United States

Site Status

Finlay Medical Research

Miami, Florida, United States

Site Status

Smith Medical Center

Dunwoody, Georgia, United States

Site Status

Sonar Clinical Research

Riverdale, Georgia, United States

Site Status

Leavitt Clinical Research

Idaho Falls, Idaho, United States

Site Status

Research Integrity

Owensboro, Kentucky, United States

Site Status

Revive Research Institute

Dearborn Heights, Michigan, United States

Site Status

Trialfinity Clinical Research Center

Hamilton, New Jersey, United States

Site Status

Albuquerque Clinical Trials

Albuquerque, New Mexico, United States

Site Status

Prime Global Research

The Bronx, New York, United States

Site Status

MultiSpecialty Clinical Research

Johnson City, Tennessee, United States

Site Status

Trio Clinical Trials

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCC-23HC009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pivotal Study of the Al-Sense Study Protocol
NCT00604838 COMPLETED PHASE1/PHASE2